Dr Jagan Mohan Reddy Bathalapalli ... Treatment usually includes: PPIs (like omeprazole): Reduce stomach acid to help the ulcer heal. H2 blockers (like famotidine): Lower acid production.

Dr. Reddy’s: Nomura has a Buy rating on the stock with a target of . Over the past 12 months, Dr Reddy’s has lost market share in key generic products (Suboxone, Vascepa, Ciprodex) due to ...

Dr. Reddy's Laboratories Ltd. closed 17.37% short of its 52-week high of 1,420.20 rupees, which the company achieved on ...

HYDERABAD: Dr Reddy’s Laboratories on Monday said it has expanded its strategic partnership with French biopharma giant Sanofi’s Indian arm, Sanofi Healthcare India Pvt Ltd (SHIPL), to bring a ...

Dr Reddy's Laboratories and Lupin are recalling products from the US market due to labelling and manufacturing issues. Dr ...

Dr Reddy's Laboratories on Monday said it has expanded its partnership with Sanofi Healthcare to introduce a novel drug for the prevention of lower respiratory tract disease in newborns.

Dr. Reddy’s Laboratories will expand its partnership with Sanofi Healthcare India (SHIPL) by launching the latter’s novel drug Beyfortus (nirsevimab) in India. Containing monoclonal antibody ...

Shares of Dr. Reddy's Laboratories Ltd. 500124 slid 1.95% to 1,176.25 Indian rupees Tuesday, on what proved to be an all-around positive trading session for the stock market, with the BSE SENSEX ...

Dr. Reddy's Laboratories has refuted media reports alleging a 25% reduction in workforce costs. The Hyderabad-based pharmaceutical giant dismissed claims of layoffs targeting high-earning ...

Pharmaceutical layoffs planned? No, says Dr Reddy's Laboratories, as the drugmaker categorically denied media reports that has undertaken workforce reduction to cut costs by around 25 per cent.

(Image: X/Twitter) Pharma major, Dr Reddy’s may cut workforce by 25% as part of its cost cutting initiatives. This is as per a report by Business Standard that indicated that the Hyderabad-based ...